Podcasts about Novo Nordisk

Inside the Biggest M&A Deals You Need to Know (Pfizer, LVMH, Atlético Madrid, Parker Hannifin)In this week's M&A episode of AmplifyME Market Maker, Anthony and Piers break down the biggest deal headlines from Apollo taking control of Atlético Madrid to LVMH's stake in Swiss movement maker Le Joux-Perret, Parker Hannifin's $9.25 billion filtration acquisition, and Burger King's China JV. The deep dive focuses on Pfizer's $10 billion battle with Novo Nordisk for Metsera, unpacking the bidding war, regulatory tensions, the strategic race for obesity drugs, and why contingent value rights (CVRs) make this deal so unusual.(00:00) Atlético Madrid, LVMH & Parker Hannifin(03:55) Pfizer vs Novo Nordisk for Metsera(05:10) How the Bidding War Escalated to $10B(12:27) Contingent Value Right(18:10) Key Deal Takeaways*****Take part in a free M&A Finance Accelerator simulation

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stock market update for November 17, 2025. Follow us on Instagram ⁠@therundowndaily⁠This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit Public.com/disclosures.

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Julia Ioffe Wants You to Know Russia Is Bigger Than Putinhttps://podcasts.apple.com/br/podcast/julia-ioffe-wants-you-to-know-russia-is-bigger-than-putin/id1845840408?i=1000735675638&l=en-GBTarcísio reativa articulações para se tornar aposta da direita para 2026https://podcasts.apple.com/br/podcast/tarc%C3%ADsio-reativa-articula%C3%A7%C3%B5es-para-se-tornar-aposta/id203963267?i=1000736091670&l=en-GB‘We needed to change the equation,' Sen. Kaine says on his vote to end shutdownhttps://podcasts.apple.com/br/podcast/we-needed-to-change-the-equation-sen-kaine-says-on/id78304589?i=1000736181362&l=en-GBTrump pardons dozens of allies who tried to overturn his 2020 election loss to Bidenhttps://podcasts.apple.com/br/podcast/trump-pardons-dozens-of-allies-who-tried-to-overturn/id78304589?i=1000736180087&l=en-GBCasamento infantil: a violência que ninguém vêhttps://podcasts.apple.com/br/podcast/casamento-infantil-a-viol%C3%AAncia-que-ningu%C3%A9m-v%C3%AA/id1477406521?i=1000736201990&l=en-GBAl-Sharaa meets with Trump at White House as Syria seeks closer ties with the Westhttps://podcasts.apple.com/br/podcast/al-sharaa-meets-with-trump-at-white-house-as-syria/id78304589?i=1000736180399&l=en-GBWhy a K-Shaped US Economy Is Raising Red Flagshttps://podcasts.apple.com/br/podcast/why-a-k-shaped-us-economy-is-raising-red-flags/id1578096201?i=1000736171958&l=en-GBPfizer and Novo Nordisk's $10bn battle over weight-loss drugshttps://podcasts.apple.com/br/podcast/pfizer-and-novo-nordisks-%2410bn-battle-over-weight/id1376303362?i=1000736372684&l=en-GBDesaprovação do governo Lula aumenta e aprovação cai após megaoperação no Rio, diz Quaesthttps://podcasts.apple.com/br/podcast/desaprova%C3%A7%C3%A3o-do-governo-lula-aumenta-e-aprova%C3%A7%C3%A3o-cai/id203963267?i=1000736405972&l=en-GBMegaoperação no Rio interrompe recuperação da popularidade de Lulahttps://podcasts.apple.com/br/podcast/megaopera%C3%A7%C3%A3o-no-rio-interrompe-recupera%C3%A7%C3%A3o-da-popularidade/id203963267?i=1000736413330&l=en-GBRODA VIVA | VICTOR DOS SANTOS | 10/11/2025https://podcasts.apple.com/br/podcast/roda-viva-victor-dos-santos-10-11-2025/id1483511325?i=1000736301338&l=en-GBMP-RJ informa STF que vai usar tecnologia 3D para analisar mortes na megaoperaçãohttps://podcasts.apple.com/br/podcast/mp-rj-informa-stf-que-vai-usar-tecnologia-3d-para-analisar/id1588271061?i=1000736508077&l=en-GBTrump faces fresh Epstein questions as new emails and files are releasedhttps://podcasts.apple.com/br/podcast/trump-faces-fresh-epstein-questions-as-new-emails-and/id78304589?i=1000736510656&l=en-GBChildren wounded by the war in Gaza share their stories as they heal in the U.S.https://podcasts.apple.com/br/podcast/children-wounded-by-the-war-in-gaza-share-their/id78304589?i=1000736510645&l=en-GBU.S. carrier in Caribbean amid Venezuela tensions and outcry over drug boat strikeshttps://podcasts.apple.com/br/podcast/u-s-carrier-in-caribbean-amid-venezuela-tensions-and/id78304589?i=1000736515095&l=en-GBTrump Promised Revenge. He's Using the DOJ to Make It Happenhttps://podcasts.apple.com/br/podcast/trump-promised-revenge-hes-using-the-doj-to-make-it-happen/id1578096201?i=1000736502131&l=en-GBQuaest: Lula mantém liderança na disputa presidencial, mas volta a ter empate técnico com Bolsonarohttps://podcasts.apple.com/br/podcast/quaest-lula-mant%C3%A9m-lideran%C3%A7a-na-disputa-presidencial/id203963267?i=1000736571627&l=en-GB‘He Knew': What Epstein Said About Trump in New Emailshttps://podcasts.apple.com/br/podcast/he-knew-what-epstein-said-about-trump-in-new-emails/id1200361736?i=1000736573426&l=en-GBUOL Prime #96:https://podcasts.apple.com/br/podcast/uol-prime-96-o-neg%C3%B3cio-da-china-feito-pelo-governador/id1574996957?i=1000736555344&l=en-GB

Vi starter med slik på bordet. Vi ser nemlig Novo Nordisk generalforsamling live i studiet - og taler om den efterfølgende. Vi vender blandt andet, hvorvidt at Novo Nordisk virkelig er kommet så godt fra start med direktør Doustdar, som Lars Rebien Sørensen påstår. Vi fejrer også en fødselar. Bang og Olufsen fylder 100 år. HURRA! Et designbrand, som de fleste har et forhold til. Men omsætningen falder - og spørgsmålet er: Er brandet stærkt nok til fremtiden? Til slut skal vi i byggemarkedet. Stark er kommet med regnskab. Og der er røde tal på bundlinjen. Men det er ikke noget, der går Starks direktør på. Det er en del af strategien fra ejerne bag. Det skal vi have forklaret. Vært: Ulrik Rosenkvist Schultz. Fast gæst: Sune Aagaard. Medvirkende: Frederik Preisler, partner i Mensch og Søren P. Olesen, CEO hos Stark Group.

Babs Drougge på P3 Nyheter förklarar morgonens stora nyheter, alltid tillsammans med programledarna för Morgonpasset i P3: Linnéa Wikblad och Branne Pavlovic. Lyssna på alla avsnitt i Sveriges Radio Play. Inför årets skidsäsong har det svenska längdlandslaget ingått ett samarbete med Novo Nordisk – läkemedelsbolaget bakom Ozempic. Nu reagerar en norsk kommentator på samarbetet, och Therese Johaug tycker att bantningsmediciner borde förbjudas inom idrotten.Sen pratar vi om att sportkanalen Sky Sports nylanserade tiktokkanal för tjejer stoppats efter bara tre dagar. Detta efter massiv kritik mot användningen av rosa filter och innehåll som handlar om Labubus, Barbies och matcha.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In the past week, breakthrough developments surrounding Ozempic and its use for weight loss have dominated health news, reflecting sweeping changes in both medical access and public perception. According to Popular Mechanics, Novo Nordisk, the pharmaceutical giant behind Ozempic and the similar injectable Wegovy, has just revealed the results of a major 71-week clinical study evaluating an oral pill form of semaglutide, the active ingredient in both Ozempic and Wegovy. This study, published in The New England Journal of Medicine, found that the daily pill achieved nearly the same results as the weekly injection, with participants losing an average of 16.6 percent of their body weight, far surpassing the 2.7 percent weight loss seen in the placebo group. About one third of those taking the pill lost more than 20 percent of their starting weight, signaling not just statistical significance but profound clinical impact. The trial also reported side effects consistent with earlier injectable versions, including increased incidences of nausea and vomiting, though these were not severe enough to derail the optimism surrounding the pill's future.Compounding these scientific advancements, the White House this week announced successful negotiations with both Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 receptor agonists—the drug class of Ozempic, Wegovy, and Zepbound—which many insurance providers had previously excluded or charged full price for. Now, eligible patients may see their out-of-pocket costs plummet from over one thousand dollars per month to a much more accessible fifty to three hundred fifty dollars depending on dosage and coverage. According to comments from Kim Fisher at the UC Davis Innovation Institute for Food and Health, these price adjustments are expected to drive a swift increase in demand and medication use, with around one in eight adult Americans having already tried some form of GLP-1 therapy.Despite the popularity and transformative outcomes touted by both consumers and medical professionals, Ozempic and related drugs are not without controversy. While these medications have reshaped the landscape for obesity and diabetes treatment, as UC Davis reports, emerging evidence indicates a need for caution and individualized care. Some patients experience notable gastrointestinal effects such as nausea and diarrhea, largely because GLP-1 drugs alter how the gut processes food and signal fullness to the brain. In addition, while fat loss can be dramatic, experts highlight that up to one quarter of the total weight lost may be from lean muscle, underscoring the importance of physical activity and adequate protein to preserve strength. Another concern echoed this week involves bone health, as rapid weight loss and restricted nutrition may inadvertently reduce bone density, especially in older adults and postmenopausal women. Leading researchers emphasize that a successful and safe weight loss journey with Ozempic demands precision nutrition, attentive exercise regimens, and regular monitoring to minimize health risks and maximize wellbeing.The intersection of celebrity culture with the Ozempic phenomenon also drew fresh attention over the past week, especially regarding Oprah Winfrey's evolving relationship with the drug. Oprah, who has long shared her struggles with weight publicly, admitted in recent interviews that she initially resisted taking Ozempic, saying she felt it was the easy way out and preferred to focus on lifestyle change. According to AOL, she reflected on her internal conflict about using medical intervention for weight loss, underscoring how the rise of drugs like Ozempic has forced a cultural reckoning over what constitutes effort, discipline, and legitimacy in personal health. While some celebrity peers openly dismiss rumors or deny any use of weight loss drugs, Oprah's decision to speak candidly about her hesitation and subsequent experiences gives voice to a wider conversation happening both in Hollywood and across the nation. As more public figures reveal their choices, the stigma of using medication to address chronic weight struggles may begin to dissipate, helping others seek support without shame.In summary, the past week has marked a pivotal moment in the ongoing Ozempic story. The introduction of a highly effective oral pill, substantial price cuts via government negotiation, and ongoing public debate about safety, efficacy, and cultural perceptions have all contributed to growing momentum. Now, as clinicians and patients alike look ahead to a future where advanced weight management tools are both more accessible and potentially safer to use, the importance of personalized guidance and health literacy has never been clearer.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

California officials misled a federal judge about policies that hide students' "gender transitions" from parents at schools, bombshell documents uncovered by a legal firm appear to show.For decades, leftists in the media and in the Democrat Party have tried to sell a simple equation: to be Latino is to be liberal. They've claimed that any resistance to their radical, anti-American agenda—whether it's open borders, defunding the police, or socialist economic policies—is racist. But that narrative was never true, and millions of Latinos are proving it wrong every day. Chris Salcedo, host of the Chris Salcedo Radio Show, the Chris Salcedo Show on Newsmax TV, and The Salcedo Storm Podcast, joins me to discuss his new book, The Rise of the Liberty-Loving Latino, where he tells the story corparate, legacy media refuses to cover: how a growing number of Hispanic Americans are standing up for faith, family, freedom, and the Constitution.Last week, the White House announced new deals that Donald Trump made with drugmakers Eli Lilly and Novo Nordisk to lower the prices of some GLP-1 and weight-loss medications. J.D. Hayworth, a former House Ways and Means member and spokesperson for the Pharmaceutical Reform Alliance, joins me to discuss what this deal truly means for American patients. Is it a real step toward affordability, or just another profit play by Big Pharma? Hayworth can explain what Congress must do next to ensure lasting savings and accountability.Becky Noble, a journalist at Red State and her Substack Gumshoe Politics, joins me to discuss the latest with Chip Roy's bill to freeze immigration and the perks of working for the Chicago Public School system.Chris SalcedoThe Rise of the Liberty-Loving Latino: A New American RevolutionPharmaceutical Reform AllianceBecky Noble at Red StateGumshoe PoliticsBecome a supporter of Tapp into the Truth: https://www.spreaker.com/podcast/tapp-into-the-truth--556114/support Tapp into the Truth on Rumble. Follow, watch the older shows, and join the live streams.“Remember Pop Rocks? Now, imagine they gave you superpowers.” Please let me introduce you to Energy Rocks! Born from the grit and ambition of a competitive athlete who wanted a better, cleaner way to fuel the body and mind, without the hassle of mixing powders, messy bottles, or caffeine crashes. Energy Rocks is a reimagining of energy into something fun, functional, and fantastically effective. A delicious popping candy energy supplement that delivers a rapid boost of clean energy and focus — anytime, anywhere. No water. No mixing. No bulky bottles. Just open, pop it in your mouth, and get ready to rock. Making any time the right time to “Get in the Zone, One Pop at a Time.”Take This Free Quiz To Find Out The Best & Worst Foods To Avoid For Joint Pain!Do you wake up in the morning with stiff joints or pain in your hips, back, knees, or elbows? Then, chances are you're feeling the effects of chronic inflammation taking its toll on your body. The good news is that it is NEVER too late to help get this under control. And the best part is certain foods help you do this naturally, without the need for prescription medications.If recent events have proven anything, you need to be as prepared as possible for when things go sideways. You certainly can't count on the government for help. True liberty requires self-reliance. My Patriot SupplySupport American jobs! Support the show! Get great products at great prices! Go to My Pillow and use promo code TAPP to save! Visit Patriot Mobile or Call (817) 380-9081 to take advantage of a FREE Month of service when you switch using promo code TAPP! Morning Kick is a revolutionary new daily drink from Roundhouse Provisions that combines ultra-potent greens like spirulina and kale with probiotics, prebiotics, collagen, and even ashwagandha. Just mix with water, stir, and enjoy!Follow Tapp into the Truth on Locals Follow Tapp into the Truth on SubstackHero SoapPatriot DepotBlue CoolersKoa CoffeeBrainMDDiamond CBDSauce Bae2nd SkullEinstokBeanstoxBelle IsleMomento AIHoneyFund"Homegrown" Boone's BourbonBlackout Coffee Co.Full Circle Brewing Co.Pasmosa Sangria  

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading: How Ozempic's maker lost its shine after creating a wonder drug.What Trump's new drug pricing deal means for people with obesity.Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

Efter børsdrama træder Bavarian Nordics formand tilbage. I dag får Novo Nordisk ny bestyrelse. Korro Bio-aktien faldt drastisk efter afbrudt Novo-projekt. Zealand Pharma dropper vægttabshåb. Ny bonusmodel i Velliv. Kritisk råstof-fund i Grønland. Flere danskere betaler topskat. Vært: Trine Duvander (trine.duvander@borsen.dk)

Die EU hat den Covestro-Deal mit Adnoc freigegeben. Nun muss noch die Bundesregierung zustimmen. Und: Bei Novo Nordisk sorgt ein Aufsichtsratsumbau für Unsicherheit.

Fredag bliver et afgørende kapitel skrevet i dansk erhvervshistorie, når Novo Nordisk aktionærer skal vælge en stort set helt ny bestyrelse og udpege Novos nye ukronede konge, Lars Rebien Sørensen, som ny bestyrelsesleder. Allerede inden generalforsamlingen har både store udenlandske og indenlandske investorer rejst kraftig kritik af forløbet. Men hvad betyder det for Novo og Lars Rebiens muligheder som ny formand at lykkes, når store investorer allerede er kritiske, inden arbejdet går i gang? Og kan selskabet overhovedet vende skuden og konkurrere mod ærkerivalen Eli Lilly, der brøler afsted med stærke produkter og voldsom vækst? Hør debatten i denne uges udgave af Bundlinjen. Gæster: Benjamin Røpke, adm. direktør, Bahne. Gitte Lillelund Bech, ejer af LillelundBech, professionelt bestyrelsesmedlem, tidl. forsvarsminister. Søren Linding, erhvervskommentator, debatredaktør, Finans Vært: Mads Ring Producer: Kasper Søegaard.See omnystudio.com/listener for privacy information.

From the research facilities of Novo Nordisk, Copenhagen-born, Lexington, Massachusetts-based Danish scientist and senior vice president JACOB STEN PETERSEN talks about his 35-year career working in developing drugs to support patients with serious chronic diseases, and his 25-year long work and personal investment in finding a cure for diabetes. Jacob further shares his thoughts on the cultures between Denmark and the US regarding the pharmaceutical industry and healthcare system.Jacob selects a work by Per Kirkeby from the SMK collection.https://open.smk.dk/en/artwork/image/KMS8278(Photographer: Greg M. Cooper)----------We invite you to subscribe to Danish Originals for weekly episodes. You can also find us at:website: https://danishoriginals.com/email: info@danishoriginals.com----------And we invite you to donate to the American Friends of Statens Museum for Kunst and become a patron: https://donorbox.org/american-friends-of-statens-museum-for-kunst

Repræsentanternes Hus stemmer ja til budgetforslag og dermed slutter regeringsnedlukningen efter 43 dage. Vestas skærer 900 stillinger, heraf 190 i Danmark. Gregers Wedell-Wedellsborg stopper i Matas og lander topjob i Canada. Stark lider milliardtab. Eli Lilly har officielt overhalet Novo viser regnskaber. Nye fund i grønlandsk mine.Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT's US deals and activism correspondent Oliver Barnes walks through the tussle that's involved lawsuits, public barbs and political drama. Clips from CNBC, Pfizer, Yahoo Finance- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading and listening:Weight-loss wars: $10bn hostile battle pits Pfizer against Novo NordiskPfizer shows hardball mettle needed to win in 2025 M&AThere is only one winner in the Pfizer Novo Nordisk showdownOzempic's unconventional origins- - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Oliver Barnes on X (@mroliverbarnes), or on Bluesky (@mroliverbarnes.bsky.social) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Hosted on Acast. See acast.com/privacy for more information.

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

AI and GLP-1s.As a healthcare reporter, we often get asked: ‘What are the top industry trends that brand and agency leaders are most focused on?' And that's our response: AI and GLP-1s.Luckily for you, this week's episode provides a taste of both.Our feature interview this week is an in-person conversation between managing editor Jack O'Brien and Curtis Sparrer, principal and co-founder of Bospar PR.Curtis flew in from San Francisco to preview the MM+M tracks at Haymarket Media's second annual AI Deciphered conference on Thursday. (Please note, last minute tickets are still available!)For Trends, pharma editor Lecia Bushak and editor-at-large Steve Madden get you up to speed on the week that was in GLP-1-land: from Pfizer muscling out Novo Nordisk for obesity drug developer Metsera, to the White House's drug pricing deal with Novo and Eli Lilly.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

En el Consultorio de Bolsa de Capital Intereconomía, Miguel Méndez, Analista independiente, comenta su visión sobre los mercados y destaca el cambio de ánimo entre los inversores. Señala que “la semana pasada arrancamos con pánico y ahora lo hacemos con muchos índices en máximos”, reflejando la rápida recuperación del sentimiento del mercado y el impulso de los principales selectivos. En materia de commodities, Méndez pone el foco en el oro, que mantiene un comportamiento positivo. Asegura que “el movimiento alcista continúa” y añade que “para ver los 5.000 dólares habrá que esperar al año que viene”, mostrando su confianza en la fortaleza del metal precioso. También analiza el caso de la farmacéutica Eli Lilly, que considera “el claro ganador frente a Novo Nordisk”. Recomienda “dejar correr la serie al alza”, aunque advierte que conviene “mantener un stop de protección en los 918 dólares”.

One of biopharma's most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer paying around $10 billion for the rights to the obesity biotech, a nearly $3 billion increase over its original bid. But while Novo Nordisk may have bowed out of that race, the company still made headlines this past week, with CEO Maziar Mike Doustdar joining Eli Lilly head David Ricks at the White House on Thursday to announce a deal that will see their GLP-1 drugs offered at about $350 per month.   This marks a significant discount to the current list prices of $1086 and $1350 for Lilly's obesity drug Zepbound and Novo's comparator Wegovy, respectively. No matter how low they go, however, the GLP-1 leaders can still be undercut by compounders, Steven Grossman, policy and regulatory consultant and author of the FDA Matters blog, told BioSpace this week.   Speaking of Lilly, the Indianapolis-based pharma had a busy week, reporting 20% weight loss in a mid-stage study of its amylin agonist eloralintide that William Blair analysts said “validates [the] amylin agonist class.” Lilly also netted two new partners, inking a $1.2 billion RNAi pact with SangeneBio to target metabolic diseases and licensing a genetic eye disease therapy from MeiraGTx Holdings for up to $475 million.   On the regulatory front, the FDA awarded the second round of priority review vouchers under its new Commissioner's National Priority Vouchers program. Unlike the first cohort of vouchers, which was announced in October, this group mostly consisted of products already on the market—with the exception of Lilly's orforglipron.   Finally, BioSpace dives into one the hottest trends in the immunology and inflammation (I&I) space—pipeline-in-a-product. Possibly motivated by blockbuster drugs like AbbVie's Skyrizi and Rinvoq and Regeneron and Sanofi's Dupixent, companies are optimizing shots on multiple goals in this lucrative space.  

El analista de Apta Negocios selecciona AIG, una estrategia en el índice dólar y Novo Nordisk

Timestamps:6:03 – Breakdown of FICO15:15 – Futures Trading Tip of the Week18:37 – Trump's $2K Tariff Plan34:46 – Burry's Shorts on NVDA & Palantir46:00 – What to Do After Becoming a Millionaire59:00 – Is Google the Sleeper AI Giant?1:04:10 – Holiday Market Play: Crypto or Stocks?1:08:20 – Trump x NVO x LLY Partnership Breakdown1:15:46 – Pre-Recession Indicators to Watch1:24:53 – CMG vs. CAVA Investment Outlook1:28:20 – End of Government Shutdown1:32:00 – Key Market Indicators for 20271:33:22 – Weekly Earnings RecapIn this week's Market Mondays, we break down everything from Trump's $2,000 plan to the future of AI and the latest market indicators signaling what's ahead for investors.We start with a deep dive into FICO scores and how they impact your financial future, then move into futures trading tips and Trump's bold plan to give every American $2,000 from tariff profits.We also discuss Michael Burry's short positions against Nvidia and Palantir, whether Google is the sleeper giant in AI, and what to do after you become a millionaire.Plus — we analyze Trump's new partnership with Novo Nordisk and Eli Lilly, what it means for biotech investors, and which markets — crypto or stocks — to focus on during the holiday season.As the government shutdown ends, we reveal key pre-recession indicators to watch, whether Chipotle (CMG) or CAVA are smart plays right now, and what signals could define the path to 2027.#MarketMondays #EarnYourLeisure #Investing #StockMarket #Crypto #FuturesTrading #TrumpEconomy #AIStocks #NVDA #Google #Palantir #NVO #LLY #FinancialEducation #WealthBuilding #RecessionPrep #EYLOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in biotech last week. On the latest edition of the BioCentury This Week podcast, BioCentury's analysts explained why Pfizer's victory for the start-up over European rival Novo Nordisk doesn't necessarily mean a broader U.S. policy shift against foreign acquisitions of domestic biotechs.Turning to ObesityWeek readouts, they discuss Eli Lilly's data for amylin monotherapy eloralintide, arguing that just as Lilly did with GLP-1 agonists, the company is again setting the benchmark by which all other molecules in the class will be measured.BioCentury's analysts also discuss takeaways from Washington Editor Steve Usdin's Commentary, which finds FDA in a crisis of politicized decisions, plummeting morale, and a hollowed workforce, and highlights from BioCentury's interview with gene therapy pioneer Jim Wilson as he rethinks the funding model for ultrarare disease therapies to keep his mission on track. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657545#ObesityWeek #Amylin #GLP1 #Eloralintide #DrugMechanism #FDA #RareDisease #GeneTherapy00:01 - Sponsor Message: Voyager Therapeutics 01:53 - Pfizer Wins Metsera08:48 - Lilly's Amylin Data13:06 - Funding Ultrarare Therapies20:51 - What's Next for FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

Dagens ämnen: 0:00 Intro 4:38 Intellego 11:58 Snapchat 19:17 Novo Nordisk och life science 26:00 Polymarket 28:58 AI 31:24 Government shutdown 33:44 Råvaror 34:33 Buffett avgår 35:40 Många intressanta case 37:18 Veckans Fill or Kill www.instagram.com/fillorkillpodden   Tack RoboMarkets! http://gorobo.pro/2aue      @RoboMarketsSE 

The federal government shutdown is still dragging on — now stretching into its second month — freezing key economic data and labor reports. This adds more uncertainty to already shaky markets, which are struggling under tariffs. Meanwhile, major developments are unfolding in the courts, from a pivotal Supreme Court case that could redefine presidential power over tariffs to an antitrust battle involving Pfizer and Novo Nordisk.At the state level, voters weighed in on key tax and spending measures that will shape local economies for years to come. A lot is happening across every level of government — and each of these stories ties back to one question: how do we keep America's economy free, competitive, and growing? In This Week's Economy, I explore this question in light of recent news. You can catch the full episode on YouTube, Apple Podcast, or Spotify.Visit: VanceGinn.comSubscribe: VanceGinn.Substack.com

S&P futures are pointing higher today. Asia equities ended higher, Europe opened with strong gains. US dollar unchanged. Treasury yields higher across tenors, JGB yields also up. Crude oil futures higher. Precious metals up with gold back above $4K. Base metals mixed. Cryptocurrencies also rallying. Risk sentiment supported on news that US Senate is nearing deal to end government shutdown with enough Democrats in support. Compromise said to involve fully funding Departments of Agriculture and Veterans Affairs for a year while partially funding other agencies through 30-Jan. Agreement guarantees laid-off federal employees will be re-hired and given backpay. Any deal would also unblock release of delayed economic data, providing colour on December rate cut prospects. White House also warned of a potentially negative Q4 GDP print from shutdown that extended past Thanksgiving. Companies Mentioned: Accor, Metsera, Pfizer, Novo Nordisk

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal's lack of guarantees on healthcare. Meanwhile, China will resume exports of Nexperia chips following a row with the Dutch government, potentially giving a boost to the autos industry which had been hit by the supply shock. In pharma news, the battle between Pfizer and Novo Nordisk for weight-loss biotech Metsera has ended, with the Danish conglomerate losing out in the $10 billion deal.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über wacklige KI-Börsen, den neuen Plan für Siemens Healthineers und was diese Woche sonst noch wichtig wird. Außerdem geht es um Palantir, Nvidia, Meta, Microsoft, ASML, SAP, Infineon, Volkswagen, Siemens, Altair, Rumble, Northern Data, Merck & Co., Amgen, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, Novo Nordisk, Eli Lilly, Robinhood und Walmart. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of groundbreaking developments that are reshaping the landscape of drug development and patient care. These stories highlight the dynamic nature of the pharmaceutical and biotechnology industries, where scientific advancements and regulatory changes are driving significant shifts.We begin with a crucial milestone in oncology treatment. The FDA has granted approval to Johnson & Johnson's Darzalex Faspro for patients with high-risk smoldering multiple myeloma. This approval is particularly significant as it provides a new therapeutic pathway for individuals with this precursor condition to active multiple myeloma, which previously had few treatment options. The drug works by targeting CD38 proteins on myeloma cells, representing a leap forward in monoclonal antibody treatments for cancer. This decision underscores the FDA's ongoing commitment to expanding treatment options for conditions with high unmet needs, potentially setting a precedent for future approvals in early-stage malignancies.Meanwhile, Gilead Sciences encountered challenges with its oncology pipeline as Trodelvy failed to meet its primary endpoint in a Phase 3 trial for first-line HR+/HER2-negative metastatic breast cancer. This outcome highlights the complexities of oncology drug development, despite previous successes in other indications. Such setbacks remind us of the inherent risks involved in bringing innovative therapies to market.In contrast, Akeso has announced positive data for ivonescimab, a PD-(L)1xVEGF bispecific antibody. The drug demonstrated significant overall survival benefits in patients with previously treated EGFR-mutated non-small cell lung cancer. This advancement underscores the therapeutic potential of bispecific antibodies in cancer immunotherapy, which continue to gain traction as they target multiple pathways involved in tumor growth and immune evasion.Regulatory incentives have also been making waves. The FDA's rollout of the second round of "national priority" voucher winners aims to accelerate drug development timelines, particularly in critical areas such as obesity. Companies like Lilly and Novo Nordisk have been recognized for their efforts, highlighting a broader strategy to bring transformative therapies to market more swiftly.On the corporate front, Bayer's proposed private equity buyout fell through due to insufficient shareholder support, reflecting ongoing financial volatility and strategic recalibrations within biotech firms. Meanwhile, CMS's introduction of a new Medicaid pricing model aims to implement "most-favored nation" pricing strategies to control drug costs, signaling potential shifts in how pharmaceutical companies approach pricing negotiations and reimbursement strategies.Technological advancements are also at the forefront of innovation. Eli Lilly has expanded its AI-driven drug discovery partnership with XtalPi, focusing on antibody development. This collaboration exemplifies how AI is increasingly being integrated into pharmaceutical research to enhance drug discovery processes.Furthermore, China's decision to lift its ban on Illumina's DNA sequencers is expected to facilitate greater access to advanced genomic technologies within the region, fostering innovation in precision medicine.Leadership changes continue to shape industry dynamics. For instance, Recursion Pharmaceuticals is undergoing executive restructuring to better align with evolving market needs and innovation strategies. These changes are crucial for maintaining competitiveness and fostering an environment conducive to scientific breakthroughs.The industry is also witnessing strategic realignmenSupport the show

Novo Nordisk opgiver kapløbet om Metsera. Jensens Bøfhus rival overtager restau­ranter.Efteråret plejer at køle boligmarkedet af, men i år tager priserne endnu et ryk op. Danske myndig­heder har hjulpet Kina med at opbygge nøglein­du­stri. Medicinalopkøb til milliarder. Kina ophæver eksport­forbud til USA. Det danske brint-marked er gået i stå. Vært: Trine Duvander (trine.duvander@borsen.dk)

Pfizer gewinnt das Wettbieten gegen Novo Nordisk und übernimmt den Adipositas-Spezialisten Metsera. Gemäss Michael Kunz, Analyst bei der Luzerner Kantonalbank, ist Pfizer jedoch dafür bekannt, Firmen teuer zu kaufen, die sich dann nicht wie gewünscht entwickeln. SMI +1.3%

En Capital Intereconomía, el Radar Empresarial puso hoy el foco en Novo Nordisk, compañía que sigue siendo protagonista del sector farmacéutico tras los últimos movimientos en su estrategia global y su nueva alianza con la india Emcure Pharmaceuticals. En la entrevista del día, Javier López, director y CEO de SilverGold Patrimonio, analizó la situación de los metales preciosos en un contexto económico global marcado por la volatilidad, la inflación y las tensiones geopolíticas. López explicó que tanto el oro como la plata mantienen su papel de refugio ante la incertidumbre y destacó que el renovado interés de bancos centrales e inversores institucionales ha reforzado su posición como activo estratégico. El experto apuntó que el oro seguirá siendo un valor defensivo en 2026, mientras que la plata gana atractivo no solo como refugio, sino también por su demanda creciente en la transición energética y la industria tecnológica. Desde SilverGold Patrimonio, indicó, la compañía ofrece planes de compra adaptados a distintos perfiles de inversor, con soluciones personalizadas para proteger el ahorro a largo plazo. En el Foro de la Inversión, participó Martina Álvarez, Directora de Ventas para Iberia de Janus Henderson, quien analizó el contexto de los mercados globales de renta fija y variable, destacando la importancia del asesoramiento activo para navegar un entorno financiero de mayor selectividad y oportunidades concretas. La jornada concluyó con el Consultorio de Herencias de Itziar Pernía Gómez, Socia Directora de Legal por Naturaleza, centrado en la adjudicación de herencias mediante cuaderno particional privado. Pernía explicó que este tipo de adjudicación sí puede ser válida, pero no exime del pago de impuestos y requiere que todos los herederos estén de acuerdo. En caso de conflicto, aclaró, el reparto puede impugnarse judicialmente. También abordó qué ocurre con bienes no inscritos en el Registro de la Propiedad y las responsabilidades derivadas de herencias aceptadas de manera privada.

En Capital Intereconomía hemos contado en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada marcada por el optimismo en los mercados y el rebote del sector tecnológico. El Ibex 35 abre al alza siguiendo la tendencia de las plazas internacionales, impulsado por la mejora del sentimiento inversor tras el acuerdo en Estados Unidos para poner fin al cierre de gobierno. En el análisis de mercados, Rodrigo Villanueva, gestor en Attitude Small Caps, explicó que “las bolsas suben mientras los bonos caen, reflejando un regreso del apetito por el riesgo”. Según el experto, los inversores están rotando hacia renta variable ante la expectativa de una pausa prolongada en los tipos de interés y mejores perspectivas de crecimiento global. El oro, por su parte, sube con fuerza, impulsado por la debilidad del dólar y la búsqueda de refugio ante la volatilidad reciente en el sector tecnológico, especialmente tras las correcciones en valores de inteligencia artificial. En el sector farma, Novo Nordisk fue protagonista al confirmar la pérdida de su acuerdo con Metsera, aunque la compañía mantendrá su apuesta por el crecimiento internacional, anunciando una alianza con la india Emcure Pharmaceuticals para distribuir y comercializar su medicamento para adelgazar bajo una nueva marca en ese mercado emergente. En el sector automovilístico, China retoma las exportaciones de chips de Nexperia, una noticia que aporta alivio a las cadenas de suministro globales y alivia las tensiones en la industria tecnológica y de semiconductores. La sesión incluyó también el consultorio de bolsa con José María Lerma, analista independiente, quien analizó oportunidades de inversión en un contexto de mercados alcistas pero con elevada selectividad, y respondió a las dudas de los oyentes sobre valores nacionales e internacionales.

Desde el año pasado, las grandes farmacéuticas libran una intensa batalla por dominar el mercado de los medicamentos para adelgazar. Aunque cada vez surgen nuevas empresas dispuestas a hacerse un hueco, hasta ahora el sector había estado liderado por dos grandes potencias: Novo Nordisk y Pfizer. Sin embargo, el equilibrio de poder se ha alterado con el reciente movimiento de la compañía estadounidense, que ha cerrado la compra de Metsera por 10.000 millones de dólares, consolidando su apuesta por los tratamientos contra la obesidad. La propia Metsera explicó que eligió la oferta de Pfizer debido a los posibles problemas antimonopolio que podrían haber surgido si aceptaba la propuesta de la farmacéutica danesa. La operación marca un punto de inflexión en un mercado en el que Novo Nordisk mantiene más del 50% de la cuota en Estados Unidos, impulsada por el éxito de sus fármacos basados en GLP-1. Con esta adquisición, Pfizer se adentra de lleno en el prometedor negocio de las píldoras adelgazantes, aunque su incorporación efectiva tardará en materializarse, ya que los productos de Metsera aún no están disponibles comercialmente. Aun así, la noticia no ha perjudicado a su rival: lejos de penalizarla, el mercado ha recibido positivamente el “revés” de Novo Nordisk, cuyas acciones subieron cerca de un 3% en la Bolsa de Copenhague. Los analistas ahora debaten si Pfizer ha pagado demasiado por Metsera, pero nadie duda del interés genuino de Novo Nordisk en la compañía. La firma danesa se incorporó a una negociación que ya estaba prácticamente cerrada entre Pfizer y Metsera, reactivando la competencia con una oferta inesperada. Durante un encuentro reciente en la Casa Blanca, el CEO de Novo Nordisk, Mike Doutsdar, incluso bromeó con Albert Bourla, director ejecutivo de Pfizer, sugiriéndole que aumentara su propuesta. Tras la contraoferta final de Pfizer, Novo Nordisk anunció que continuará desarrollando su propio portafolio, especialmente su versión oral del fármaco Wegovy, llamada a convertirse en el formato estrella de los medicamentos para adelgazar en 2026.

In this week's episode of Dividend Talk we kick off with Kimberly-Clark's surprise move to buy Kenvue, asking if it's a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.Novo Nordisk's obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer's high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on's double-digit dividend hike and Simon Property Group's steady income growth for REIT investors.Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.In the listener Q&A, we cover:Dividend tax strategies and EU exit taxes How to handle rising wealth taxes as a dividend investor Fair-value analysis vs Morningstar valuations Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition Thoughts on Unilever's upcoming Magnum spinoff SEE YOU ON THE INSIDE!!Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj

Mamdani se convierte en el primer alcalde musulmán de Nueva York.La demócrata, Mikie Sherrill conquista la gobernación de NJ.Caminar más podría ayudar a retrasar el Alzheimer.ICE detiene a educadora en una guardería hispana de Chicago.Presidente Trump acuerda mejores precios con Eli Lili y Novo Nordisk.Aranceles ante la Corte Suprema.Hayan muerto a un padre, antes del juicio por la muerte de su hija.Ponte al día con lo mejor de ‘La Edición Digital del Noticiero Univision' con Carolina Sarassa y Borja Voces.

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's Headlines: House Democrats want no-longer-Prince Andrew to testify about his ties to Jeffrey Epstein. Meanwhile, Nancy Pelosi announced her retirement, with California Sen. Scott Wiener emerging as the establishment pick — though AOC's ex–campaign manager Saikat Chakrabarti plans to run too. A federal judge ruled again that Trump must fully fund SNAP benefits by today, but the DOJ is appealing. Trump also struck a deal with Eli Lilly and Novo Nordisk to cap Ozempic-style drugs at $50 for Medicare and Medicaid patients next year. In smaller but iconic justice news, the D.C. “sandwich guy” who threw a sub at an ICE agent was found not guilty of assault. The Heritage Foundation is in “open revolt” after its president defended Tucker Carlson for hosting white supremacist Nick Fuentes. Staffers, including members of its antisemitism task force, have quit. Meanwhile, FIFA announced a mysterious new “peace prize” ahead of the World Cup draw in D.C., which insiders say Trump demanded after missing out on a Nobel. And Tesla's board is set to hand Elon Musk a $1 trillion compensation deal. Resources/Articles mentioned in this episode: Politico: House Oversight Democrats call on embattled royal Andrew Windsor to testify - Live Updates Politico: California's attorney general endorses Scott Wiener to succeed Pelosi NYT: Judge Orders Trump Administration to Fully Fund SNAP Benefits This Month WaPo: Trump, long fixated on ‘fat drug,' announces deal to lower its price WaPo: Jury finds D.C. ‘sandwich guy' not guilty of assaulting officer WaPo: Heritage staff in open revolt over leader's defense of Tucker Carlson Axios: Trump teased as possible first FIFA Peace Prize winner CNBC: Elon Musk expected to prevail in Tesla shareholder vote over CEO's $1 trillion pay plan  Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

¡Emprendeduros! En este episodio Rodrigo nos da una actualización de mercado donde habla del estatus del mercado, del mercado de empleo y de la manufactura en el pais. Nos da los reportes de ingresos de Palantir, Uber, Shopify, AMD, Novo Nordisk, McDonald's y AppLovin. Después habla de la compra de Kenvue por Kimberly Clark y de la semana ocupada de Elon Musk. Finalmente contestara unas preguntas de los Emprendeduros. ¡Síguenos en Instagram! Rodrigo: https://www.instagram.com/rodnavarro Emprendeduros: https://www.instagram.com/losemprendeduros Para mas información sobre nuestro fondo visita: https://emprendedurosventures.com/

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk's $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk's history of exceeding investor expectations. Plus, U.S. airlines are beginning to cancel flights to manage shutdown-strained staffing of air traffic controllers, and Warren Buffett issued a warning on AI.  Dr. Mehmet Oz - 21:43Walter Isaacson - 38:56 In this episode:Dr. Mehmet Oz, @DrOzJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

//The Wire//2300Z November 6, 2025////ROUTINE////BLUF: RIOTS ERUPT IN BIRMINGHAM AS SPORTS MATCH TRANSITIONS FROM GENERAL HOOLIGANISM INTO LARGER GEOPOLITICAL CONFLICT. OVAL OFFICE PRESS CONFERENCE HALTED DUE TO PHARMA EXEC COLLAPSING SUDDENLY.// -----BEGIN TEARLINE------International Events-United Kingdom: A state of civil unrest has emerged following a soccer match inflaming local tensions. Following a much-anticipated soccer match between a team from Tel Aviv and the local Aston Villa team in Birmingham, riots broke out overnight as rival gangs took their disputes to the street. Riot police were deployed to the stop the roving bands of "youths" from destroying property and generally causing disarray. Throughout the day today, the unrest has continued as long-held social tensions in Birmingham reached the boiling point. Over 700x police officers have been called up for duty tonight as the riots are planned to become much more significant with tonight's match against Tel Aviv.-HomeFront-Washington D.C. - This afternoon the White House announced a special press conference on the topic of pharmaceuticals. Most notably the press conference was called to announce a partnership with Novo Nordisk to lower the price of the Ozempic drug when purchased through the TrumpRX program.Analyst Comment: The press conference was abruptly cut short after Gordon Findlay, one of the senior executives of Novo Nordisk (the maker of Ozempic) collapsed in the Oval Office during the live broadcast. Dr. Oz, who was a part of the conference tried to render aid to him, and the rest of the press conference was delayed while Findlay received medical treatment. It's not certain why he dropped, but the White House stated that he was okay but feeling a bit lightheaded after the incident.-----END TEARLINE-----Analyst Comments: Once more, the misfortune of our friends across the pond gives Americans absolutely critical insight as to how things might go if a similar series of events were to pop off here in a major American city. For obvious reasons, a relatively nondescript soccer match is less about the sport and more about social and political issues, thus the unrest concerns. In short, it's a fairly kinetic and complex situation that serves in many ways as an indicator of the future to come.Birmingham has become a huge focal point for migrant housing, and these riots were not the work of the indigenous English. However, as with all soccer hooliganism, the rioting is almost never just one-sided. In this case, some (not all) Maccabi Tel Aviv fans were banned by British authorities from the Aston Villa stadium after starting a riot themselves, according to police. This resulted in two things happening simultaneously: the Islamic population of Birmingham rejoiced at this perceived geopolitical victory (and celebrated by breaking things and causing a ruckus), while many other Maccabi Tel Aviv fans lashed out in anger (again, also by breaking things and causing a ruckus). However, during the general state of unrest, rival gangs of mostly black and Islamic migrants (which had no interest in soccer) started fighting amongst themselves, adding in more diversity to the evening fray. Others still showed up to protest for more political purposes, but remained relatively calm throughout the evening. When the police arrived to restore order as this was getting underway last night (the day before the match), the more active elements of the crowds turned on them, targeting them with fireworks (which were probably used due to yesterday being Guy Fawkes Night). It is this unrest that continued from last night, throughout the day today, to tonight as well (the night of the match). So this is a two-day affair, not just a one-and-done scuffle, but a more prolonged period of unrest.In short, what's going on in Birmingham right now is more or less a state of mild pandem

Eric Criscuolo, Market Strategist at the NYSE, recaps a week where markets pulled back as Tech lost steam and defensive sectors gained ground. The Fed cut rates as expected, but Chair Powell's hawkish tone cooled hopes for further easing. Political headlines added uncertainty, with Democrats outperforming on Election Day and the Supreme Court questioning Trump-era tariffs. M&A activity surged, led by Kimberly Clark's $50B bid for Kenvue and a pharma bidding war between Pfizer and Novo Nordisk. Investors now look ahead to key earnings, economic data, and the impact of the government shutdown as the year-end trading calendar tightens.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

A.M. Edition for Nov. 5. Democrats notched major victories last night, prompting President Trump's ire on social media. WSJ editor Aaron Zitner breaks down what the results mean for both parties and how they could shape the national political landscape going into the 2026 midterms. Plus, Republican senators meet at the White House this morning as the government shutdown becomes the longest in history. And we look at the competition facing weight-loss giant Novo Nordisk. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus, Republican senators meet at the White House this morning as the government shutdown becomes the longest in history. And we look at the competition facing weight-loss giant Novo Nordisk. Caitlin McCabe hosts.  Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sara Eisen, Carl Quintanilla, and David Faber kicked off the hour with a slew of fresh data on the economic front - and more on what investors need to know as the Supreme Court kicks off Day 1 of arguments around the legality of President Trump's global tariffs... Plus: Bank of America CEO Brian Moynihan joined the team with his read on the economy, live from the company's first investor day in more than 15 years - while the CEO of Lemonade gave his take on how AI is changing the insurance business as those shares surge post-results.  Also in focus: the growing bidding war between Novo Nordisk and Pfizer that could impact the future of the weightloss market... and a deep-dive on what's driving Pinterest shares to their worst day on record. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices